E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial

Bewersdorf, J. P., Stahl, M., Taylor, J., Mi, X., Chandhok, N. S., Watts, J., … Stein, E. M. (2023). E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial. Leukemia, 37(12), 2512–2516. https://doi.org/10.1038/s41375-023-02050-4